Aurinia Pharmaceuticals Inc. — Director's Dealing 2021

Sep 14, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aurinia Pharmaceuticals Inc. (AUPH)
CIK: 0001600620
Period of Report: 2021-09-10

Reporting Person: Solomons Neil (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-09-13	Common Shares	M	150000	$3.20	Acquired	287299	Direct
2021-09-10	Common Shares	S	150000	$19.84	Disposed	137299	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-09-13	Stock Option (right to buy)	$3.2	M	150000	Disposed	2027-02-09	Common Stock (150000.0)	Direct

Footnotes

F1: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date.

F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3: The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $19.77 to $19.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

F4: The shares subject to the option are fully vested and immediately exercisable. They vested in thirty-six equal monthly installments from the grant date.